Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, double-blind Phase 2/3 trial to assess efficacy and safety of AM-111 in the treatment of surgery-induced hearing loss following cochlear implantation

Next Previous
Search
Trial Profile

A randomized, placebo-controlled, double-blind Phase 2/3 trial to assess efficacy and safety of AM-111 in the treatment of surgery-induced hearing loss following cochlear implantation

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 25 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimapitide (Primary)
  • Indications Hearing loss
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms REACH
  • Sponsors Altamira Therapeutics

    • Most Recent Events

    • 25 Jun 2015 According to an Auris Medical media release, Auris Medical and Cochlear Ltd. will collaborate on this trial in the United States.
    • 28 May 2015 Enrolment is expected to begin in the third quarter of 2016, according to an Auris Medical media release.
    • 04 May 2015 The IND submitted for this trial has been approved, according to an Auris Medical media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top